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Background: Thirty percent of children with food allergy are allergic to more than one food. Previous studies on
oral immunotherapy (OIT) for food allergy have focused on the administration of a single allergen at the time. This
study aimed at evaluating the safety of a modified OIT protocol using multiple foods at one time.
Methods: Participants underwent double-blind placebo-controlled food challenges (DBPCFC) up to a cumulative
dose of 182 mg of food protein to peanut followed by other nuts, sesame, dairy or egg. Those meeting inclusion
criteria for peanut only were started on single-allergen OIT while those with additional allergies had up to 5 foods
included in their OIT mix. Reactions during dose escalations and home dosing were recorded in a symptom diary.
Results: Forty participants met inclusion criteria on peanut DBPCFC. Of these, 15 were mono-allergic to peanut and
25 had additional food allergies. Rates of reaction per dose did not differ significantly between the two groups
(median of 3.3% and 3.7% in multi and single OIT group, respectively; p = .31). In both groups, most reactions
were mild but two severe reactions requiring epinephrine occurred in each group. Dose escalations progressed
similarly in both groups although, per protocol design, those on multiple food took longer to reach equivalent
doses per food (median +4 mo.; p < .0001).
Conclusions: Preliminary data show oral immunotherapy using multiple food allergens simultaneously to be
feasible and relatively safe when performed in a hospital setting with trained personnel. Additional, larger,
randomized studies are required to continue to test safety and efficacy of multi-OIT.
Trial registration: Clinicaltrial.gov NCT01490177
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Food allergy is the leading cause of fatal and recurring
anaphylaxis in children and teenagers in both Europe
and the United States [1-3]. The current standard of care
is to practice strict avoidance of the food allergens and
have injectable epinephrine readily available, in case of
accidental exposure [1]. Unfortunately, unintentional in-
gestion is a common occurrence [4].
Oral and sublingual allergen-specific immunotherapies
have been proposed as possible methods of desensitization* Correspondence: pbegin@stanford.edu
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stated.and, possibly, of induction of tolerance, with several prior
studies having shown some success in using these ap-
proaches for single specific food allergens such as milk
[5-11], egg [10-14], peanut [15-20], and hazelnut [21].
These monotherapies appeared relatively safe when con-
ducted in a supervised and controlled setting, with severe
reactions requiring epinephrine being rare.
Despite these promising results, there is lack of infor-
mation regarding simultaneous administration of mul-
tiple foods within the same treatment. This is an
important caveat considering that 30% of food allergic
participants under 18 years old are estimated to be aller-
gic to more than one food [22-24]. This estimate has
been reported to increase to 70% when consideringtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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gle food allergies, these participants experience a greater
decrease in quality of life [26], are more likely to suffer
from dietary deficiencies [27] and are less prone to spon-
taneously outgrowing their allergies [28].
Since OIT relies on allergen ingestion on a daily basis,
mostly at home, the main concerns with simultaneous
allergen administration are about safety. Previous studies
using non-specific anti-IgE stimulation showed that
binding of only 200 to 500 of the 250, 000 surface IgE
molecules on a basophil are required to trigger de-
granulation [29]. A concern is that administration of mul-
tiple allergens simultaneously would in theory result in an
increased number of specific IgE molecules being simul-
taneously bound and cross-linked on mast cells and baso-
phils, increasing the risk of reaching this threshold. It is
also unknown whether such an approach would affectA
B
Figure 1 OIT trial design including (A) screening and trial flow chart a
dose depends on number of allergen in mix (4000 mg per allergen).treatment efficacy. One could hypothesize that immuno-
logic responses and memory responses to each food would
be allergen specific; however, synergic effects cannot be
excluded.
The primary endpoint (safety) of our investigation was
the occurrence of allergic reactions throughout the course
of the study, comparing food allergic participants with ei-
ther peanut alone or multiple foods in their treatment.
Methods
This phase 1 study was performed in a single center in a
hospital setting with Institutional Review Board ap-
proval, under Investigational New Drug (IND) approval.
Participant selection, study medication and design are
described in the Additional file 1. Briefly, participants
older than 4 years were eligible for inclusion if they had
proven sensitivity to the food allergen documented bynd (B) immunotherapy protocol timeline. Amount of maintenance
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specific IgE greater than 2kU/L to peanut as well as
positive allergic reaction in a double-blind placebo-
controlled oral food challenge (DBPCFC) up to a cu-
mulative dose of 182 mg as per Bock’s criteria [30].
Further DBPCFC were also performed following the
same protocol to nuts, sesame seed, dairy or egg to docu-
ment additional food allergies. Exclusion criteria (which in-
cluded severe anaphylaxis requiring ICU admission and
poorly controlled asthma) are listed in the Additional file 1.
Participants who reacted only to peanut on their inclu-
sion DBPCFC were assigned to the single OIT group
while those who reacted to additional foods were assigned





Number of participants 25 15
Median Age in yrs. (range) 8 (4–25) 10 (5–46)
Male 14 (56%) 8 (53%)
Coexisting atopic disease
Atopic Dermatitis 17 (68%) 8 (53%)
Allergic Rhinitis 13 (52%) 9 (60%)
Asthma 17 (68%) 10 (66%)
Baseline testing to peanut (median and range)
SPT in mm 15 (7–25.5) 12 (7–22)
Specific IgE in kUA/L 90.4 (2.43-100) 80 (3.66-100)
DBPCFC step eliciting symptoms
(mg protein)
50 (0.1-100) 25 (1.6-100)
Symptoms upon peanut DBPCFC
Skin 20 (80%) 12 (80%)
Upper airways 18 (72%) 12 (80%)
GI 17 (68%) 12 (80%)
Lower airways 6 (24%) 3 (20%)
Other food allergies meeting DBPCFC criteria for inclusion
Walnut 14 (56%) N/A
Cashew 13 (52%) N/A
Pecan 7 (28%) N/A
Milk 7 (28%) N/A
Egg 6 (24%) N/A
Sesame 6 (24%) N/A
Almond 5 (20%) N/A
Hazelnut 3 (12%) N/A
Number of food in mix
2 6 (24%) N/A
3 8 (32%) N/A
4 5 (20%) N/A
5 6 (24%) N/Aregimen (up to five food allergens could be used) was cus-
tomized to what the participant was found to be allergic
to by DBPCFC. The OIT protocol for both groups (single
OIT and multi OIT) consisted of three phases: (1) the
initial escalation day (or modified rush day), (2) home
dosing with biweekly visits for dose escalations and (3)
the maintenance phase (Figure 1B) which are detailed
in the Additional file 1. Participants were instructed to
take oral cetirizine (dosed as per each product insert)
1 hour before home doses and trained on the use of
epinephrine (see details in the Additional file 1). The
primary goal of the OIT was to achieve a 10-fold in-
crease from initial DBPCFC threshold. The dosing
protocol was designed to continue dose increases up to
a daily maintenance dose of 4000 mg protein of each
allergen (up to 20,000 mg cumulative dose for those
on 5 allergens).
Serological analysis
Sera at baseline and at 12 months were analyzed for
food-specific IgE and IgG4 levels by immunoCAP FEIA
(Thermofisher Scientific/Phadia, Kalmazoo, MI) when
available. IgE antibody levels < 0.1 kUA/L and IgG4 anti-
body levels <0.01 kUA/L were considered undetectable.
IgE antibody levels between 0.1 and 0.35 kUA/L cur-
rently have an undetermined clinical significance.
Statistical analysis
Clinical characteristics and safety data were compared
between the groups using student T test for continuous
and Pearson’s chi-square for dichotomic variables. Dose
progression was measured as time to reach 10-fold in-
crease from initial cumulative dose eliciting a reaction
on DBPCFC to peanut as well as doses of 300, 1000 and
4000 mg protein per food allergen. Groups were com-
pared with Kaplan-Meier curves using the Breslow test.Table 2 Reaction rates
Multi (n = 25) Single (n = 15) p-value
Initial escalation day
Reactions (Reaction rate) 15 (60%) 6 (40%) .22
Epinephrine use 0 0 1.00
Dose escalations
Total doses 603 doses 277 doses
Median reaction rate [range] 3.4% [0–23.1] 3.7% [0–16.6] .31
Epinephrine use 0 0 1.00
Home dosing
Total doses 12030 doses 7830 doses
Median reaction rate [range] 3.1% [0.6-29.2] 2.9% [0.1-59.0] .65
Epinephrine use (per dose) 2 (0.02%) 2 (0.03%) .67
Epinephrine use
(per participant)
2 (8%) 2 (13%) .62
Bégin et al. Allergy, Asthma & Clinical Immunology 2014, 10:1 Page 4 of 8
http://www.aacijournal.com/content/10/1/1Changes in serologies were assessed by Wilcoxon
matched-pairs signed rank test.
Results
A total of 40 participants ranging in age from 4 to
46 years met inclusion criteria on DBPCFC and were en-
rolled in an OIT protocol. Fifteen (15) with single pea-
nut allergy documented by DBPCFC were assigned to
peanut single OIT. The 25 remaining eligible partici-
pants received multi OIT for multiple allergens. Detailed
allergen combinations in the multi group are available in
the Additional file 1. Clinical characteristics of each
group are compared in Table 1. There were no statisti-
cally significant differences between the groups. Both
groups were also comparable with regards to theirA
B
C
Figure 2 Symptom occurrence with (A) initial escalation day, (B) dosepeanut allergy SPT, specific IgE and DBPCFC results. Al-
lergy evaluation results for other foods included in the
multi group are available in the Additional file 1.
There were no serious adverse events in the study. Over
the study period, there were 5 drop outs for reasons which
included non-compliance with study medication (n = 4)
and change of residence (n = 1). One participant in the
multi OIT group was unable to increase doses due to ec-
zema flares that prevented initial escalation and was cate-
gorized a treatment failure (n = 1). These participants
were included in safety analyses but censored at the point
where they were excluded. Overall, a total of 277 hospital
escalation doses and 7,830 home doses were given in the
peanut monotherapy group; while 603 hospital escalation
doses and 12,030 doses were given to the participantsescalations and (C) home dosing during OIT to multiple foods.
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doses were missed consecutively by any one participant,
based on dose diary review.
Most reactions to multiple food OIT doses were mild,
with abdominal pain being the most frequently reported
symptom, both in hospital setting and at home. Figure 2
presents symptom profiles per doses while Table 2 reports
distribution of participants’ individual reaction rates for
each OIT phase. Most participants experienced symptoms
on the initial escalation day (60%) which were mild. Our
data showed no statistical difference in adverse event rate
or severity when comparing customized multi OIT regi-
mens (i.e. there were not higher rates of allergic reactions
with particular or with greater number of foods in mix).
Participants in the monotherapy group had a similar
reaction profile (Additional file 1: Figure S1). Of note,
one patient in this group reported frequent mild abdom-
inal cramping with 369 of 630 home doses (59%)
(not shown in Additional file 1: Figure S1). She was able
to progress normally with dose escalations and these re-
actions eventually subsided while on maintenance.
Table 2 compares reaction rates in both groups, which
did not differ significantly.
Two severe reactions requiring epinephrine occurred in
each group after home dosing (Additional file 1: Table S3).
In the monotherapy group, one participant had abdominal
pain and wheezing within 20 minutes of food allergen
ingestion and was immediately treated with injectableFigure 3 Kaplan-Meier curves showing time to dose of 300 mg (A), 10
time to reach the dose corresponding to a 10 fold increase from the thresh
from χ2 analysis were calculated using Breslow method.epinephrine; symptoms resolved within 6 minutes of treat-
ment. Another participant had urticaria and wheezing
within 40 minutes of food allergen ingestion and was im-
mediately treated with injectable epinephrine; symptoms
resolved within 5 minutes of treatment. In the multi-
allergen group, one participant had wheezing and angio-
edema around the eyes within 25 minutes of food allergen
ingestion, and the reaction resolved within 3 minutes fol-
lowing administration of injectable epinephrine. The other
participant on multi OIT with a severe reaction had ab-
dominal pain, urticaria, and wheezing within 35 minutes
of food allergen ingestion and was immediately treated
with injectable epinephrine; symptoms resolved within
6 minutes of treatment.
Kaplan-Meier curves showing time to reach a 10-fold
increase in threshold dose of food allergen protein, as well
as time to reach a dose of 300 mg, 1000 mg and 4000 mg
food allergen protein are presented in Figure 3. Partici-
pants undergoing monotherapy reached these 4 secondary
endpoints significantly faster than those on multi-allergen
OIT (p = .004, p < .0001, p = .0007, and p = .005, for re-
spective outcomes) which was expected given each aller-
gen represented only a fraction of the whole dose in the
latter group. COX regression analysis showed no statistical
difference in dose progression comparing number or com-
binations of foods in the OIT mix (data not shown).
One year into OIT, peanut-specific IgE remained un-
changed in both groups while peanut specific IgG400 mg (B), and 4000 mg (C) per allergen in mix. Panel D shows
old at which the patient reacted to peanut on initial DBPCFC. P-values
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in multi and single OIT respectively) (Figure 4). Similar
trends were found to other foods in the multi OIT group
(Additional file 1: Figure S2).
Discussion
In this phase 1 study, we have shown that participants
allergic to multiple foods can be safely desensitized to
up to five foods simultaneously using a modified OIT
protocol. Despite the increasing interest in food OIT in
recent years, the safety or efficacy of using multiple food
flour/powder allergens in parallel has, to our knowledge,
not been published. These findings are particularly rele-
vant considering the already high and likely growing
number of food allergic participants who are allergic to
more than one food allergen [22-25].
The multi OIT study was designed as a proof of con-
cept, phase 1 study; therefore, safety measurements wereFigure 4 Comparison of peanut-specific IgE (A) and IgG4 (B) at
baseline and after one year of OIT. *p = 0.001; **p = 0.008.the primary endpoint. The rate of reactions observed in
the multi-allergen OIT group was within the acceptable
range for an OIT study and was similar to a reference
cohort of peanut mono-allergic participants undergoing
the same protocol to peanut only. This supports the
view that it is not the diversity or multiplicity of the food
allergen binding surface IgE but rather the total dose of
allergen administered that determines OIT reactions.
However, this data should be viewed as proof of concept
data until randomized, controlled, double-blinded phase
2 studies with larger sample sizes are performed.
In previous single OIT studies, overall reaction rates
tended to vary, possibly due to differences in escalation pro-
tocols, allergens, selection of participants or use of anti-
histamine pre-medication [7-9,13-15,19]. However, severe
reactions needing epinephrine injections have been consist-
ently shown to be an occurrence, albeit rare, when per-
forming OIT. In our study, 2 participants from each group
required epinephrine during the study period. Although the
number of allergens did not seem to increase the risk of se-
vere reactions, a state of continual vigilance is needed to
perform OIT. As most reactions occurred at home (includ-
ing those severe reactions requiring injectable epinephrine),
participants and families carry reaction medications at all
times and are educated on the proper use of injectable epi-
nephrine and on the recognition of severe reactions that
warrant its use. It is also important that the food doses be
from a verifiable and reproducible source, that they be care-
fully measured and cross-checked by clinical staff and
stored and dispensed from an appropriate facility.
We chose to proceed with a single dose of each food in
an equal protein stoichiometric ratio. In some smaller chil-
dren that are slow eaters, the process of eating their dose
could take up to 1 hour with a mix of 5 nuts at full dose. In
such cases, it would not have been feasible to wait in be-
tween foods for the occurrence of a reaction. Our final
maintenance dose was 4000 mg per allergen. The optimal
long term maintenance dose for food OIT has not been
identified yet and may need to be individualized. More
studies are needed to determine this parameter of OIT
which may have an impact on subject compliance with
ingestion.
Except for one participant who was excluded due to ec-
zema flares and two drop-outs, all participants reached a 10
fold increase in their reaction threshold during the study
period. The median time at which participants on single al-
lergen OIT reached this dose was 14 weeks earlier than for
those on the multi-allergen therapy. Participants undergo-
ing multi-allergen OIT also took more time reaching the
300 mg, 1000 mg and 4000 mg doses. This delay is to be
expected since there were up to 5 food allergens given sim-
ultaneously and the dose for each individual food allergen
was divided evenly. Importantly, this phase 1 study demon-
strates that it is possible and feasible to test the effect of
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forming single immunotherapy in sequence for patients, a
process that could take many years for patients who are
multi-sensitized to food allergens.
Although no SCORAD was calculated, it is worth not-
ing that the participant that failed the initial dose escal-
ation had significantly more severe eczema than other
participants, for which he reported a history of systemic
treatment and a clear relation with ingestion of food
allergens. The eczema was active at enrolment despite
topical treatment.
Despite showing proper dose progression, our study did
not prove treatment efficacy. To measure true clinical toler-
ance, participants would have to stop their maintenance
dose and demonstrate sustained unresponsiveness on a
challenge after weeks to months of avoidance, which was
beyond the scope of this study [31].
Serological analysis did show an increase in peanut-
specific IgG4 similar to the monotherapy group. Peanut-
specific IgE were stable after one year but this was not
unexpected, as previous reports have shown that food
specific IgE may start decreasing below baseline levels
only after the first year of therapy [8,13,16,32].
One limitation to this study was the absence of
randomization. This said, this is not a requirement for
phase 1 studies. The single and multiple allergic partici-
pant were part of the same protocol. We cannot rule out
that the molecular sensitization profile could be different
in multi-allergic participants that exhibit cross-reactivity
with other nuts as it was not tested fully. Regardless,
these proof of concept results show that OIT to multiple
foods might be as safe as peanut OIT in single-allergic
participants.
In conclusion, using a modified OIT protocol we have
shown that simultaneous desensitization to multiple
foods is feasible and worthy of further study. The reac-
tion profile compared to that of peanut single-allergic
participants undergoing monotherapy and participants
showed comparable changes on serological examination.
At this time, OIT should be considered an experimental
treatment and should be conducted by trained research
personnel in a hospital setting. Randomized, placebo-
controlled phase 2 multicenter trials are needed to con-
tinue to determine safety and efficacy parameters of
multi OIT in multi-allergic participants.Additional file
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